rofecoxib has been researched along with Duodenal Diseases in 1 studies
Duodenal Diseases: Pathological conditions in the DUODENUM region of the small intestine (INTESTINE, SMALL).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almendingen, K | 1 |
| Larsen, LN | 1 |
| Fausa, O | 1 |
| Bratlie, J | 1 |
| Høstmark, AT | 1 |
| Aabakken, L | 1 |
1 trial available for rofecoxib and Duodenal Diseases
| Article | Year |
|---|---|
Selective COX-2 inhibition affects fatty acids, but not COX mRNA expression in patients with FAP.
Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Aged; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygen | 2010 |